Crinetics Pharmaceuticals Stock Price, News & Analysis

Crinetics Pharmaceuticals (NASDAQ: CRNX) has announced an upcoming R&D Day event scheduled for June 26, 2025, from 9:00 AM to 12:00 PM ET in New York, with both in-person and virtual attendance options. The event will showcase updates on the company's early-stage pipeline assets, development strategies, and plans for long-term value creation. Key presentation topics will include their NDC platform with CRN09682 for NETs and beyond, TSH antagonist developments for Graves' disease and thyroid eye disease (TED), and SST3 agonist research for autosomal polycystic kidney disease (ADPKD). The event will conclude with a live Q&A session.

Crinetics Pharmaceuticals (CRNX) has granted equity-based compensation to 20 new non-executive employees on June 10, 2025. The compensation package includes 74,000 non-qualified stock options with an exercise price of $33.08 per share and 48,850 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in equal annual installments over four years. These awards were granted under the company's 2021 Employment Inducement Incentive Award Plan, specifically designed for new hires in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals (NASDAQ: CRNX) has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025, scheduled for June 3-5, 2025 in New York. The company's management will deliver a presentation on Thursday, June 5, 2025, at 12:50 p.m. Eastern Time. Investors can access the live and archived webcast through the Events & Presentations page in the Investors section of Crinetics' website. One-on-one meetings with management can be arranged through conference representatives.

Crinetics Pharmaceuticals (NASDAQ: CRNX) will present new research on its investigational drugs at the AACE Annual Meeting 2025 in Orlando. Key highlights include: 1. A post-hoc analysis showing paltusotine, their lead candidate, demonstrated rapid and durable IGF-1 control in surgically naïve acromegaly patients, with positive results: - 3/4 patients in PATHFNDR-1 and all 4 in PATHFNDR-2 achieved IGF-1 normalization - Median IGF-1 remained stable over 24 months in ACROBAT Advance 2. Research on symptom burden showing patients on current injectable treatments experience symptom exacerbations on 32% of days. 3. Real-world evidence revealing 54% of acromegaly patients discontinue current standard therapy. The company awaits a PDUFA date of September 25 for paltusotine in the U.S., with regulatory reviews progressing in both U.S. and EU.

Crinetics Pharmaceuticals (NASDAQ: CRNX) has granted equity awards to 35 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The awards include 152,475 non-qualified stock options with an exercise price of $30.68 per share and 101,800 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in equal annual installments over four years. These grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals (CRNX) reported Q1 2025 financial results and business updates. The company has $1.3B in cash and investments, expected to provide runway into 2029. Key highlights include: FDA review for paltusotine's NDA for acromegaly is on track with a PDUFA date of September 25, 2025. The EMA validated paltusotine's MAA with a potential decision in H1 2026. Q1 financials showed revenues of $0.4M, R&D expenses of $76.2M, and a net loss of $96.8M. The company plans to initiate multiple Phase 3 trials in H2 2025, including CALM-CAH for CAH treatment and CAREFNDR for carcinoid syndrome. An R&D Day is scheduled for June 26, 2025, to share updates on early-stage pipeline developments.

Crinetics Pharmaceuticals (NASDAQ: CRNX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial performance and provide a business update.

Participants can join via phone using domestic (1-833-470-1428) or international (1-404-975-4839) dial-in numbers with Conference ID: CRNXQ1. Alternatively, they can access the live webcast through the Events section of Crinetics' website. Participants are advised to connect 15 minutes before the call starts to ensure timely access. The webcast recording will be available later in the Investor Relations section of www.crinetics.com.

Crinetics Pharmaceuticals (CRNX) has announced new equity grants under its 2021 Employment Inducement Incentive Award Plan. On April 10, 2025, the company's Compensation Committee awarded:

- Non-qualified stock options to purchase 124,950 shares with an exercise price of $26.85 per share
- 84,725 restricted stock unit (RSU) awards

These grants were made to 26 new non-executive employees as employment inducements. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest in four equal annual installments. All grants are subject to continued employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals (CRNX) announced two major regulatory milestones for paltusotine, its novel once-daily oral treatment for acromegaly. The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for review and granted Orphan Drug Designation (ODD) on February 27, 2025.

Paltusotine, the first oral selectively-targeted somatostatin receptor type 2 nonpeptide agonist, demonstrated success in two Phase 3 trials, meeting all primary and secondary endpoints. The trials showed statistically significant biochemical control and symptom improvement compared to placebo, with good tolerability.

The MAA submission includes data from 18 clinical trials. This follows the FDA's acceptance of the New Drug Application with a PDUFA date of September 25, 2025. The ODD status provides potential benefits including 10-year market exclusivity in the EU and reduced regulatory fees.